Immunwork, Inc. was founded in 2014. We focus on the research, development, and commercialization of a class of new drugs, which are created based on our proprietary technology platform, for treating multiple types of cancer, a number of severe indications in autoimmune, osteoporosis, infectious, and central nervous system diseases, pathological blood clots, rejection reaction in organ transplantation, and other selected severe clinical conditions.
Currently, many companies and academic groups are racing to establish new methods for preparing antibody drug conjugates (ADCs), bispecific antibodies, multivalent antibodies, and various forms of immuno-oncology products. It is hopeful that those various advancements will bring about major therapeutic breakthroughs in the treatment of various types of cancer. Our technology platform enables the design of a class of new drugs, which we term “T-ETM pharmaceuticals”. These new drug molecules contain both targeting (T) and effector (E) moieties. As evidenced by the product candidates that have already been designed and prepared, our technology can be used to prepare ADCs, bispecific and multi-specific antibodies, and various products in versatile configurations, which have improved product homogeneity, drug payloads, target-binding valency, and consistency in the manufacturing process. The T-E configurations are expected to achieve increased efficacy and safety.
Our existing portfolio of product candidates has expanded much beyond the scopes of applications being pursued in current “magic bullet” concept and bispecific antibody approaches. The T-E molecular platform should be applicable for designing many more other product candidates not illustrated on this website. As personalized and precision medicine is becoming a major trend in pharmaceutical development, the modular design feature of T-E pharmaceuticals is especially suitable for preparing a new generation of therapeutics.
Together, everyone achieves more! We are seeking corporate partners to collaborate the development of our T-E product candidates or to utilize our T-E technology platform to design new drugs for various disease indications.
Contact
If interested, please email us at BD@immunwork.com.
Immunwork, Inc ｜Nangang District, Taipei City, Taiwan 115 ｜ +886-2789-8773
Taiwan’s population of just 23 million people and contested political status should, in theory, harm its chances of becoming a globally relevant clinical trials hub. In fact, these two factors…
Dr Yuan-Hung Hsu, President of MegaPro Biomedical, discusses the Taiwanese company’s evolution into a late-stage nanomedicine company, with two platforms targeting precision medicine. He highlights MPB 1523, a heavy-metal-free MRI…
Taiwan’s investment culture remains heavily oriented toward semiconductors and electronics, and few investors are yet convinced to commit capital to biotech Dr. Lin, Founder and Chief Scientific Officer of Tripartite…
A genuinely healthy lifestyle can help prevent neurodegenerative disease Charles S.Y. Yang discusses how his background in physics and quantum sensing led to the founding of MagQu, pioneering ultra-sensitive blood…
For two decades the case for running a clinical trial in Asia was essentially arithmetic: the same study, for less money. That argument has not gone away, but it is…
Contemporary Taiwan finds itself navigating unprecedented healthcare challenges, having transitioned into a super-aged society with unexpected speed, compounded by one of the lowest birth rates globally. In 2024, to secure…
In recent years, Taiwan’s policymakers have been aggressively deploying a multi-layered industrial strategy – and doing so with the benefit of watching earlier regional movers stumble – in an effort…
Over the past three decades, Taiwan’s elderly population – defined as individuals aged 65 and older – has expanded by a staggering 152 percent. This demographic shift has introduced complex…
Biotechnology has long been a strategic priority for Taiwan’s economic development, standing alongside ICT and semiconductors as a key pillar of growth for the island. Driven by a highly educated…
Semiconductors: Silicon Powerhouse Taiwan and semiconductors – the microscopic chips inside virtually every electronic device – are inextricably linked. For a modestly sized island, Taiwan’s semiconductor dominance is extraordinary: through…
Taiwan runs one of the most cost-effective universal healthcare systems in the world, delivering near-universal coverage to 23 million people at a fraction of what comparable systems cost elsewhere. At…
Despite its modest market size, Taiwan is proving a popular investment destination for pharma and medtech multinationals. While the island’s semiconductor industry garners more headlines and revenues, life sciences is…
See our Cookie Privacy Policy Here
